Gotham Asset Management LLC Sells 120,833 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Gotham Asset Management LLC trimmed its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 25.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 347,015 shares of the company’s stock after selling 120,833 shares during the quarter. Gotham Asset Management LLC’s holdings in Maravai LifeSciences were worth $1,891,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC increased its stake in shares of Maravai LifeSciences by 7.3% in the fourth quarter. SG Americas Securities LLC now owns 33,046 shares of the company’s stock worth $180,000 after buying an additional 2,239 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Maravai LifeSciences by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 30,076 shares of the company’s stock worth $164,000 after buying an additional 2,851 shares during the period. Performa Ltd US LLC increased its stake in shares of Maravai LifeSciences by 614.3% in the fourth quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock worth $27,000 after buying an additional 4,300 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Maravai LifeSciences by 12.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 70,828 shares of the company’s stock worth $387,000 after buying an additional 7,946 shares during the period. Finally, Bleakley Financial Group LLC increased its stake in shares of Maravai LifeSciences by 30.1% in the fourth quarter. Bleakley Financial Group LLC now owns 41,691 shares of the company’s stock worth $227,000 after buying an additional 9,657 shares during the period. 50.25% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on MRVI. Robert W. Baird decreased their target price on shares of Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating on the stock in a research note on Tuesday. Stifel Nicolaus set a $5.00 price objective on shares of Maravai LifeSciences in a research report on Friday, March 21st. Craig Hallum reduced their price objective on shares of Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday. Morgan Stanley reduced their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 25th. Finally, Bank of America reduced their price objective on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.64.

Maravai LifeSciences Stock Up 7.1%

NASDAQ:MRVI opened at $2.10 on Friday. The firm’s 50-day moving average price is $2.09 and its 200-day moving average price is $4.05. The company has a market capitalization of $534.11 million, a PE ratio of -1.28 and a beta of 0.19. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. Maravai LifeSciences Holdings, Inc. has a 1-year low of $1.67 and a 1-year high of $11.56.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $46.85 million during the quarter, compared to analysts’ expectations of $44.01 million. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The firm’s revenue was down 26.9% on a year-over-year basis. On average, equities analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.